TipRanks
Go Ultimate55% OFF

FDC Ltd. (FDC) AI Stock Analysis

IN:FDC

FDC Ltd.

(NSE:FDC)

Select Model
Rating:63Neutral
Price Target:INR 401.00â–²(5.22% Upside)
Action:reiterated
Date:08/28/26

The score is driven primarily by strong financial stability (especially the low-leverage balance sheet and steady revenue growth), partially offset by weak technicals showing a clear downtrend and bearish momentum. Valuation is supportive but not a major catalyst, with a reasonable P/E and modest dividend yield.

Positive Factors
Low leverageA very conservative capital structure limits refinancing risk and preserves financial flexibility. The growing equity base also gives FDC capacity to support product development, manufacturing investment, and market expansion without relying heavily on external borrowing.
Negative Factors
Margin pressureDeclining margins reduce the amount of profit generated from each unit of revenue and may indicate rising costs, product-mix pressure, or weaker pricing power. If the trend persists, revenue growth may translate less effectively into earnings and returns.

FDC Ltd. (FDC) vs. iShares MSCI India ETF (INDA)

-30%-25%-20%-15%-10%-5%0%5%IN:FDC-13.75%INDA-10.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 62.31B
Dividend Yield
1.30%
Average Volume (3M)
12.99K
Price to Earnings (P/E)
19.8
Beta (1Y)
0.85
Revenue Growth
10.20%
EPS Growth
38.95%
Country
India
Employees
7,076
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

FDC Ltd. Business Overview & Revenue Model

Company Description

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectiv...

How the Company Makes Money

FDC makes money primarily by selling pharmaceutical and healthcare products. Revenue is generated from (1) sales of prescription medicines supplied to healthcare providers, hospitals, and pharmacies, and (2) sales of other healthcare products sold th...

FDC Ltd. Financial Statement Overview

Summary

Financials are anchored by a very conservative balance sheet (extremely low debt and a strengthening equity base), supporting flexibility and lower risk. Revenue growth has been steady and profitability remains solid, but margins have trended down from earlier highs. Cash flow is the main weak spot due to notable free-cash-flow volatility and a sharp latest-year decline, reducing visibility.

Income Statement

72Positive

Balance Sheet

90Very Positive

Cash Flow

56Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue22.89B21.71B21.08B19.35B17.84B15.26B
Gross Profit9.74B9.18B8.36B6.51B11.28B9.78B
EBITDA3.79B4.39B4.15B4.40B3.01B3.30B
Net Income3.13B2.81B2.67B3.05B1.94B2.16B
Balance Sheet
Total Assets31.76B29.19B27.14B24.68B23.43B22.70B
Cash, Cash Equivalents and Short-Term Investments6.22B5.23B5.37B4.75B4.84B5.39B
Total Debt128.20M154.65M211.68M205.19M283.20M322.04M
Total Liabilities5.07B4.34B4.33B3.71B3.62B3.14B
Stockholders Equity26.69B24.85B22.81B20.97B19.82B19.57B
Cash Flow
Free Cash Flow0622.92M2.67B1.27B418.21M291.08M
Operating Cash Flow02.49B3.64B2.21B1.55B1.62B
Investing Cash Flow0-1.59B-2.47B-170.83M111.35M-1.45B
Financing Cash Flow0-925.39M-913.47M-2.02B-1.80B-98.37M

FDC Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price381.10

Price Trends

50DMA346.69Positive
100DMA373.21Positive
200DMA370.54Positive

Market Momentum

MACD7.41Negative
RSI68.63Neutral
STOCH86.94Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Positive. The current price of 381.10 is above the 20-day moving average (MA) of 347.97, above the 50-day MA of 346.69, and above the 200-day MA of 370.54, indicating a bullish trend. The MACD of 7.41 indicates Negative momentum. The RSI at 68.63 is Neutral, neither overbought nor oversold. The STOCH value of 86.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FDC.

FDC Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:FDC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:STARIN:STAR74OutperformINR 98.55B15.39―0.48%11.28%55.18%
IN:BLISSGVSIN:BLISSGVS69NeutralINR 68.94B40.82―0.24%20.59%27.16%
IN:FDCIN:FDC63NeutralINR 61.32B19.81―1.30%10.20%38.95%
IN:ORCHPHARMAIN:ORCHPHARMA62NeutralINR 49.89B502.87――10.83%-89.83%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 34.04B11.64――9.43%132.94%
IN:INDOCOIN:INDOCO50NeutralINR 19.23B63.42―0.09%10.75%―

* General Sector Average

Performance Comparison

0%100%200%300%IN:FDCIN:BLISSGVSIN:INDOCOIN:ORCHPHARMAIN:STARIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:FDC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:FDCFDC Ltd.381.15-60.77-13.75%
IN:BLISSGVSBliss Gvs Pharma Limited616.65463.43302.47%
IN:INDOCOIndoco Remedies Limited215.85-57.11-20.92%
IN:ORCHPHARMAOrchid Pharma Limited846.0056.707.18%
IN:STARStrides Pharma Science Ltd1037.8079.888.34%
IN:UNICHEMLABUnichem Laboratories Limited504.1533.707.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 28, 2026